G-CSF employing neuroprotection study for ischemic stroke -Phase 2 clinical trial-(GENESIS-2) - G-CSF employing neuroprotection study for ischemic stroke -Phase 2 clinical trial-(GENESIS-2)

Tokai University, School of Medicine, Division of Neurology, Department of Internal Medicine.0 个研究点目标入组 100 人开始时间: 2011年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Splenomegaly or splenic lesions on echo. 2.Leukocytosis more than 15000/mm3 3.Past history of G-CSF treatment. 4.Plan for percutaneous angiography or bypass operations. 5.Difficult to perform MRI. 6.Past histries of symptomatic intracranial hemorrhage, bleeding tendency or coagulating disorders. 7.Hyper reactivity to G-CSF. 8.Congestive heart failure or uncontrollable angina. 9.Thrombocytopenia(less than 140000/mm3) 10.Liver dysfunction(AST(GOT),ALT(GPT) more than 100 IU/L) 11.Renal dysfunction (creatinine 1.5mg/dl and more) 12.Difficult to continue this trial due to social problems, etc. 13.Join other clinical trials. 14.Inappropriate to enroll in this trial by the judgment of the doctor.

发起方

Tokai University, School of Medicine, Division of Neurology, Department of Internal Medicine.